Another significant finding was that tolerability, as measured by premature discontinuation rates in trials, was also numerically the best with carvedilol (although again the difference did not reach statistical significance), making a case for its increased use among sicker patients needing a β blocker.
← all excerpts
Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.
1
—
—